AbbVie Forecasts Adjusted EPS for 2026 Amid Strong Revenue Outlook
AbbVie has provided updated financial guidance for the year ahead, forecasting adjusted earnings per share (EPS) of $13.87 to $14.07 in 2026 and projecting total revenue between approximately $67.6 billion. The company also expects Q3 EPS to range from $3.84 to $3.88. CEO Robert Michael highlighted the strong performance, noting double-digit sales growth and progress on its pipeline of innovative medicines as key drivers. The guidance reflects continued confidence in AbbVie's business strategy following recent developments, including a planned acquisition that is expected to bolster future earnings potential.
Tickers: $ABBV
Topics: financial performance pharmaceuticals pipeline development